Found 86 clinical trials
Targeted PARP or MEK/ERK Inhibition in Patients With Pancreatic Cancer
This early phase I trial aims to determine how cobimetinib, olaparib, temuterkib, or onvansertib works in patients with pancreatic cancer. Validation of cobimetinib, or olaparib, temuterkib, and onvansertib molecular targets will be explored by comparing pre-treatment biopsies with post-treatment specimens. This knowledge will help design future biomarker driven trials to …
- 2 views
- 18 Apr, 2022
- 1 location
CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma
This phase Ib/II trial studies the side effects and best dose of CMP-001 and how well it works when given together with INCAGN01949 in treating patients with stage IV pancreatic cancer and other cancers except melanoma. CMP-001 is made up of a short piece of DNA that is packaged in …
- 0 views
- 15 Jun, 2022
- 2 locations
ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer
This phase II trial studies the side effects of ONC201 and paclitaxel and how well they work in treating patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer that has come back (recurrent), or that does not respond to treatment (refractory). ONC201 is the first in its class …
- 1 views
- 30 May, 2022
- 1 location
Exploring HIFU as a Treatment for Rectal and Other Pelvic Cancers
The hypothesis of the study is that high intensity focused ultrasound (HIFU) can be used safely to treat rectal and pelvic cancer. The study consists of two trials exploring the use of HIFU in rectal and pelvic cancer to establish the safety and potential efficacy of HIFU in this instance. …
- 3 views
- 15 Feb, 2022
- 1 location
Study of Sirolimus in Patients With Advanced Pancreatic Cancer
Pancreatic cancer is a highly malignant tumor of the digestive system.In China, the annual mortality/morbidity of pancreatic cancer is as high as 0.88:1, and the morbidity and mortality are still on the rise. The 5-year survival rate of pancreatic cancer patients in the United States is only 8%, among which …
- 3 views
- 13 Feb, 2022
- 1 location
WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases
Funding Source - FDA OOPD This phase I trial studies the side effects and best dose of WSD0922-FU for the treatment of glioblastoma, anaplastic astrocytoma, or non-small cell lung cancer that has spread to the central nervous system (central nervous system metastases). WSD0922-FU is a targeted treatment which blocks the …
- 27 views
- 24 Mar, 2022
- 3 locations
Evaluation of (Surgery and Endoscopy) in Management of Indeterminate Common Bile Duct Stricture
Evaluate the lower indeterminate CBD strictures trying to reach possible diagnosis by all available methods i.e brush cytology ,bile aspirate cytology , tissue biopsy ,imaging studies and laboratory work up then treatment of the patient either endoscopically or surgically according to the etiology.
- 0 views
- 08 Dec, 2021
- 1 location
Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
Patients may be considered if the cancer has come back, has not gone away after standard treatment or the patient cannot receive standard treatment. This research study uses special immune system cells called AGAR T cells, a new experimental treatment. The body has different ways of fighting infection and disease. …
- 0 views
- 28 Apr, 2022
- 1 location
Study on the Safety and Effectiveness of UCB-NK Cell Infusion in the Treatment of Advanced Gastric Cancer and Gastroesophageal Cancer
This study is an open, single infusion, cell infusion dose /method exploration study. In patients with gastric cancer and gastroesophageal cancer without effective treatment, the safety of UCB-NK cell immunotherapy was evaluated and the preliminary curative effect results were obtained.
- 0 views
- 24 Jan, 2021
- 1 location
DCE-CT of Thoracic Tumors as an Early Biomarker for Treatment Monitoring in Comparison With Morphologic Criteria
DCE-CT of thoracic tumors as an early biomarker for treatment monitoring in comparison with morphologic criteria. Rationale of the clinical investigation For the evaluation of response to anti-tumoral therapy in thoracic tumors, merely morphologic information is often not sufficient for early response evaluation as dimensions of the oncologic lesions are …
- 0 views
- 14 Feb, 2021
- 1 location